Jason N. Butler

JMP’s Jason N. Butler reiterated a Market Perform rating on MannKind Corporation (NASDAQ: MNKD), while noting that “Afrezza remains in limbo as we await clarity on the commercialization plan and funding options.” Earnings Miss The company reported its 4Q15 earnings below the...

Four companies in the healthcare and pharmaceuticals sectors posted mixed results that left analysts at JMP Securities mostly feeling good. Adeptus Health Inc's (NYSE: ADPT) closed Friday up nearly 2 percent on strong quarterly results. JMP analyst Peter L. Martin expects Adeptus shares...

In a report published Monday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $53.00 to $75.00. In the report, JMP Securities noted, “The completion of two-year carcinogenicity studies...

In a report published Thursday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $34.00 to $53.00. In the report, JMP Securities noted, “ETC-1002 demonstrates compelling efficacy and safety...

In a report published Wednesday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Depomed (NASDAQ: DEPO), and raised the price target from $10.00 to $11.00. In the report, JMP Securities noted, “Acquisition of migraine asset makes strategic and financial sense;...

In a report published Friday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Aastrom Biosciences (NASDAQ: ASTM), but lowered the price target from $3.00 to $2.00. In the report, JMP Securities noted, “Progress continuing with enrollment in Phase 2b DCM trial;...